drugset / Trial / NCT06239714
A Study to Evaluate SGB-3403 in Healthy Volunteers and Subjects With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending doses (MAD) of SGB-3403 when single administered subcutaneously to healthy volunteers and multiple administered subcutaneously to subjects with elevated LDL-C to evaluate the safety, tolerance, PK, and PD.
Timeline
- Start
- 2024-02-18
- Primary completion
- 2025-02-18
- Completion
- 2025-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SGB-3403 | Unknown | — | Subcutaneous |
| Background | Atorvastatin | Small molecule | — | — |